Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology

Przemysław R. Kac,Fernando González-Ortiz,Andreja Emeršič,Maciej Dulewicz,Srinivas Koutarapu,Michael Turton,Yang An,Denis Smirnov,Agnieszka Kulczyńska-Przybik,Vijay R. Varma,Nicholas J. Ashton,Laia Montoliu-Gaya,Elena Camporesi,Izabela Winkel,Bogusław Paradowski,Abhay Moghekar,Juan C. Troncoso,Tammaryn Lashley,Gunnar Brinkmalm,Susan M. Resnick,Barbara Mroczko,Hlin Kvartsberg,Milica Gregorič Kramberger,Jörg Hanrieder,Saša Čučnik,Peter Harrison,Henrik Zetterberg,Piotr Lewczuk,Madhav Thambisetty,Uroš Rot,Douglas Galasko,Kaj Blennow,Thomas K. Karikari

DOI: https://doi.org/10.1038/s41467-024-46876-7

IF: 16.6

2024-03-23

Nature Communications

Abstract:Abstract Blood phosphorylated tau (p-tau) biomarkers, including p-tau217, show high associations with Alzheimer’s disease (AD) neuropathologic change and clinical stage. Certain plasma p-tau217 assays recognize tau forms phosphorylated additionally at threonine-212, but the contribution of p-tau212 alone to AD is unknown. We developed a blood-based immunoassay that is specific to p-tau212 without cross-reactivity to p-tau217. Here, we examined the diagnostic utility of plasma p-tau212. In five cohorts ( n = 388 participants), plasma p-tau212 showed high performances for AD diagnosis and for the detection of both amyloid and tau pathology, including at autopsy as well as in memory clinic populations. The diagnostic accuracy and fold changes of plasma p-tau212 were similar to those for p-tau217 but higher than p-tau181 and p-tau231. Immunofluorescent staining of brain tissue slices showed prominent p-tau212 reactivity in neurofibrillary tangles that co-localized with p-tau217 and p-tau202/205. These findings support plasma p-tau212 as a peripherally accessible biomarker of AD pathophysiology.

multidisciplinary sciences

What problem does this paper attempt to address?

### The Problem the Paper Attempts to Solve

This paper aims to investigate the diagnostic performance of phosphorylated tau protein (p-tau212) as a pathological marker for Alzheimer's disease (AD) and to develop a blood test method to quantify this pathological change. Specifically, the research team developed an immunoassay method that specifically recognizes p-tau212 without cross-reacting with p-tau217. By evaluating the performance of plasma p-tau212 in five independent cohorts, the paper demonstrates its high accuracy in AD diagnosis and its ability to detect amyloid and tau pathology.

### Main Findings
- **Antibody Specificity**: Two sheep monoclonal antibodies were developed, targeting p-tau212 and p-tau217 respectively. Experimental results showed that these antibodies have high specificity.
- **Immunohistochemical Staining**: The p-tau212 antibody showed strong neurofibrillary tangles (NFTs) staining in brain tissue sections of AD patients, similar to the staining pattern of the p-tau217 antibody.
- **Diagnostic Performance**: Plasma p-tau212 exhibited high diagnostic accuracy in multiple cohorts, especially in distinguishing AD patients from those with other neurodegenerative diseases. Compared to p-tau181 and p-tau231, p-tau212 showed higher diagnostic accuracy and fold change.
- **Correlation Analysis**: Plasma p-tau212 showed significant correlation with amyloid and tau pathology markers, further supporting its validity as a pathological marker for AD.

In summary, this paper validates the value of p-tau212 as an important biomarker for early diagnosis and pathological prediction of Alzheimer's disease through various experiments.